Skip to content
Learn More


iBio Inks 3D Bioprinting Agreement

August 19, 2019

iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has entered into a Master Services Agreement (“MSA”) with Lung Biotechnology PBC, a subsidiary of United Therapeutics Corporation (NASDAQ:UTHR), to produce recombinant human collagen (“rhCollagen”)-based bioink for 3D bioprinted organ transplants. iBio will collaborate with Lung Biotechnology PBC to scale-up production of rhCollagen in tobacco plants using …

Read More

iBio Announces First Agreement for Fill-Finish Services

June 19, 2019

NEW YORK, June 19, 2019 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced the activation of its new cGMP sterile fill-finish services operation via the signing of a supply agreement with a clinical-stage biopharmaceutical company developing breakthrough gene and cell therapies (the “Customer”). Earlier in June, iBio introduced its new …

Read More

iBio Launches New Sterile Fill-Finish Services

June 3, 2019

NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today introduced new cGMP sterile fill-finish capabilities for pharmaceutical products, including monoclonal antibodies, viral vectors, and other biologics. Designed for clients with preclinical and clinical stage programs, the operation is housed in the Company’s 135,000 square foot CDMO facility …

Read More

iBio Announces Appointment of Thomas F. Isett to Board of Directors

April 1, 2019

Accomplished Life Science Executive with Deep Bioprocess Experience NEW YORK, April 01, 2019 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO), a biologics contract manufacturer and product developer with proprietary, “green” technologies for biopharmaceutical production, today announced the appointment of Thomas F. Isett to its Board of Directors, effective immediately. Mr. Isett is an accomplished executive …

Read More

iBio and CC-Pharming Hold First Design and Strategy Meeting

October 2, 2018

Texas Meeting Initiates Plan to Bring Economical, Plant-Derived Rituximab to China Market NEW YORK, Oct. 02, 2018 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) today announced the beginning of a four-day design and strategic planning meeting with executives and technical experts from CC-Pharming Ltd of Beijing China at iBio’s development and manufacturing facility in Bryan …

Read More